My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novartis AG Common Stock (NY:NVS)

149.12 +2.70 (+1.84%)

Official Closing Price Updated: 7:00 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

VXUS Has Delivered Better Returns Than IEFA Over the Past 5 Years. Should It Be in Your Portfolio? ↗

Today 7:05 EDT

The Vanguard Total International Stock ETF's (VXUS) outperformance stems from where it invests.

Via The Motley Fool

Topics ETFs

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗

June 05, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer...

Via MarketBeat

IEFA: Why This Fund Is One of the Best International ETFs ↗

June 04, 2026

Yesterday's slow-growing economies might be tomorrow's best places to invest.

Via The Motley Fool

Topics ETFs

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors ↗

April 08, 2026

Via Chartmill

Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗

June 04, 2026

The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca

Via Talk Markets

Topics Economy

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 02, 2026

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Via The Motley Fool

Topics Artificial Intelligence

Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗

June 02, 2026

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗

June 01, 2026

This little-discussed pipeline program could prove to be a big success.

Via The Motley Fool

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗

May 27, 2026

A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.

Via The Motley Fool

Topics ETFs

Pediatrics Medicine Market Size, Industry Report By 2035 ↗

May 22, 2026

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Via Talk Markets

Topics Economy

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Via The Motley Fool

Topics Artificial Intelligence ETFs

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗

May 18, 2026

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

Via MarketBeat

Topics Credit Cards ETFs Economy

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗

May 08, 2026

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across...

Via MarketBeat

PTCT Q1 2026 Earnings Transcript ↗

May 08, 2026

PTCT Q1 2026 Earnings Transcript

Via The Motley Fool

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout ↗

May 06, 2026

The biotech stock skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Via Investor's Business Daily

Incyte (INCY) Q2 2025 Earnings Transcript ↗

April 28, 2026

Incyte (INCY) Q2 2025 Earnings Transcript

Via The Motley Fool

Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales ↗

April 28, 2026

Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.

Via Investor's Business Daily

Better Pharma Dividend Stock: Novartis vs. Merck ↗

April 17, 2026

Both are great stocks to buy in the current environment, but which one is the better bet?

Via The Motley Fool

Topics Intellectual Property

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat

April 14, 2026

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...

Via MarketMinute

Topics Bankruptcy Earnings Economy

Big Pharma Deepens AI Ties. What It Means For Novo, Novartis. ↗

April 14, 2026

Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday. And they won't be the last pharma giants to do so.

Via Investor's Business Daily

Topics Artificial Intelligence

The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)

April 13, 2026

As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche...

Via Finterra

Topics Economy Initial Public Offering

3 Low-Volatility ETFs for Peace of Mind in Turbulent Times ↗

April 13, 2026

Amid confusion about the future trajectory of the war in Iran, the possibility of a continued ceasefire, and the potential implications for the price of oil—and the market in general—it's...

Via MarketBeat

Topics ETFs

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗

April 01, 2026

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Via The Motley Fool

Topics Earnings Economy World Trade

Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗

April 01, 2026

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

Via The Motley Fool

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to...

Via MarketMinute

Could Investing $10,000 in VYMI Make You a Millionaire? ↗

March 30, 2026

If you want to be a millionaire faster than the S&P 500 index can deliver, this international dividend stock ETF could be the ticket.

Via The Motley Fool

Topics ETFs Stocks

Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline ↗

March 27, 2026

Novartis expands allergy portfolio with $2B acquisition of Excellergy Inc. and their next-gen anti-IgE therapy Exl-111.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.